Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies. Issue 1 (2nd January 2019)

• Record Type: Journal Article
• Authors: Sethi, Tarsheen K.; Reddy, Nishitha M.
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 1(2019)
• Page Start: 6
• Page End: 18
• Publication Date: 2019-01-02
• Subjects: PCNSL -- frontline -- approach; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2018.1466296
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Primary central nervous lymphoma (PCNSL) is a rare extra-nodal subtype of non-Hodgkin lymphoma and most cases are of diffuse large B-cell lymphoma histology with an aggressive presentation. The treatment of PCNSL has evolved over the years from radiation alone to multi-agent chemotherapy with the goal of minimizing long-term toxicity. Recent studies have evaluated autologous stem cell transplant as consolidation in eligible patients with success. The prognosis of relapsed disease remains poor and hence the emphasis is on effective and less toxic frontline strategies. Our growing understanding of the pathogenetic pathways in PCNSL is giving way to an exciting new era of targeted and immunotherapy options with the potential for inclusion in upfront therapy in the future. This review critically evaluates the current evidence including ongoing studies for the frontline treatment of PCNSL.